Holen Sie sich die Stockscreener-App
0.7819
23.13%
0.1469
Schlusskurs vom Vortag:
$0.635
Offen:
$0.6416
24-Stunden-Volumen:
1.66M
Relative Volume:
2.76
Marktkapitalisierung:
$43.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.50M
KGV:
-1.0457
EPS:
-0.7477
Netto-Cashflow:
$-27.75M
1W Leistung:
+45.74%
1M Leistung:
+16.20%
6M Leistung:
-18.78%
1J Leistung:
-17.70%
1-Tages-Spanne:
$0.632
$0.794
1-Wochen-Bereich:
$0.5068
$0.794
52-Wochen-Spanne:
$0.5068
$1.915
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.7819 | 35.44M | 0 | -34.50M | -27.75M | -0.7477 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - news.alphastreet.com
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - news.alphastreet.com
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - marketscreener.com
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech redesigns cancer trial to seek faster FDA approval - Stock Titan
PDS Biotechnology Q4 2025 Earnings Call Transcript - MarketBeat
Published on: 2026-03-28 11:50:07 - baoquankhu1.vn
Aug Breakouts: Whats the analyst consensus on PDS Biotechnology CorporationMarket Trend Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
PDS Biotechnology to announce Q4 and full year results on March 30 with clinical and corporate update - Traders Union
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - The Manila Times
PDS Biotech pairs 2025 results with a clinical update on March 30 - Stock Titan
PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday - Defense World
Will PDS Biotechnology Corporation stock go up in YEARPortfolio Profit Report & Safe Entry Momentum Tips - baoquankhu1.vn
Block Trades: Can PDS Biotechnology Corporation stock outperform in a bear market2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
PDSB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PDS Biotechnology (PDSB) CEO receives 548,782-share stock option award - Stock Titan
[Form 4] PDS Biotechnology Corp Insider Trading Activity - Stock Titan
PDS Biotechnology (PDSB) awards 150,000 stock options to Chief Scientific Officer - Stock Titan
PDS Biotechnology (PDSB) CMO receives grant of 300,000 stock options - Stock Titan
PDS Biotechnology grants 300,000 options to executive | PDSB SEC FilingForm 4 - Stock Titan
PDS Biotechnology (PDSB) director Ilian Iliev receives grant of 54,876 stock options - Stock Titan
PDS Biotechnology director granted 54,876 options | PDSB SEC FilingForm 4 - Stock Titan
Director option grant at PDS Biotechnology (PDSB) totals 54,876 options - Stock Titan
PDS Biotechnology (PDSB) director awarded 54,876 stock options in new grant - Stock Titan
PDS Biotechnology receives Nasdaq notice for minimum bid price deficiency - Investing.com Australia
Nasdaq warns PDS Biotechnology (NASDAQ: PDSB) on $1.00 bid price rule - Stock Titan
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB) - The Wall Street Transcript
PDS Biotech Announces Amended Protocol for Phase 3 Trial - National Today
PDSB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
PDS Biotech (NASDAQ: PDSB) highlights HPV16 trial gains and pipeline - Stock Titan
Will PDS Biotechnology Corporation stock outperform Dow Jones indexMarket Movers & Consistent Profit Focused Trading Strategies - mfd.ru
PDS Biotechnology Amends Late-Stage Trial for PDS0101 to Support Accelerated Approval Pathway in HPV16-Positive Head and Neck Cancer - marketscreener.com
PDS Biotech amends Phase 3 trial to add accelerated approval path - Investing.com
LiveRamp Holdings, Inc. has announced a partnership with Scowtt - Bitget
Nucor has announced that Jack Sullivan has been promoted to Chief Financial Officer, Treasurer, and Executive Vice President of the company. - Bitget
PDS Biotechnology Corporation (PDS Biotech) recently announced that it has made significant amendments to the study protocol of its Phase III clinical trial, Versatile-003. - Bitget
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):